Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 20 of 20 entries
View as:

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00016874 Org: User:
Start: 12/31/00 End: 01/31/08 Due: 01/31/09

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

Phase: N/A Priority: Normal
NCT ID: NCT00098436 Org: User:
Start: 09/30/04 End: 08/31/08 Due: 08/31/09

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00304005 Org: User:
Start: 07/31/05 End: 08/31/08 Due: 08/31/09

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00064051 Org: User:
Start: 01/31/03 End: 08/31/08 Due: 08/31/09

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00282022 Org: User:
Start: 09/30/05 End: - Due: -

3-AP in Treating Patients With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00054015 Org: User:
Start: 12/31/02 End: 01/31/08 Due: 01/31/09

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Phase: N/A Priority: Normal
NCT ID: NCT00083187 Org: User:
Start: 11/30/05 End: 08/31/08 Due: 08/31/09

Combination Chemotherapy in Treating Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00024323 Org: User:
Start: 03/31/01 End: 06/30/03 Due: 06/30/04

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00112554 Org: User:
Start: 03/31/05 End: 03/31/08 Due: 03/31/09

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00049686 Org: User:
Start: 04/30/02 End: 01/31/08 Due: 01/31/09

VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00004216 Org: User:
Start: 08/31/99 End: 01/31/08 Due: 01/31/09

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00064064 Org: User:
Start: 01/31/03 End: 08/31/08 Due: 08/31/09

3-AP in Treating Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006218 Org: User:
Start: 05/31/00 End: 01/31/08 Due: 01/31/09

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00070538 Org: User:
Start: 06/30/03 End: 01/31/08 Due: 01/31/09

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00049699 Org: User:
Start: 10/31/02 End: 01/31/08 Due: 01/31/09

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00064090 Org: User:
Start: 03/31/03 End: 01/31/08 Due: 01/31/09

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00025129 Org: User:
Start: 03/31/01 End: 05/31/04 Due: 05/31/05

3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00004213 Org: User:
Start: 05/31/98 End: 01/31/08 Due: 01/31/09

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00354276 Org: User:
Start: 05/31/06 End: - Due: -

VNP20009 in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00006254 Org: User:
Start: 05/31/00 End: 01/31/08 Due: 01/31/09